ArticleCancer immunology, immunotherapy : CII2023

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.

Johanna Bendell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.